Moderna On Cathie Wood's Radar Ahead Of Q2 Results: Ark Boosts Stake In COVID-19 Vaccine Maker By $12M This Week
Portfolio Pulse from Shanthi Rexaline
Cathie Wood's Ark Investment Management has increased its stake in Moderna, Inc. (NASDAQ:MRNA) by $12M this week, ahead of the company's Q2 results. The purchases were made through Ark Genomic Revolution ETF (CBOE: ARKG), which now holds 244,271 shares of Moderna, accounting for 1.26% of the portfolio. Moderna is expected to report a loss of $4.03 per share, a significant reversal from a profit of $5.24 in the year-ago period. The company is also developing a personalized cancer vaccine with Merck & Co., Inc. (NYSE:MRK).
July 26, 2023 | 6:47 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Ark Genomic Revolution ETF's performance may be influenced by its increased stake in Moderna, especially given the upcoming Q2 results.
The ETF's performance is likely to be influenced by the performance of its holdings. With the increased stake in Moderna, any significant movement in Moderna's stock could impact the ETF.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Merck's collaboration with Moderna on a personalized cancer vaccine could potentially impact its stock.
Merck's collaboration with Moderna on a personalized cancer vaccine could provide a potential growth driver for the company, which could influence its stock.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 60
NEUTRAL IMPACT
Moderna's stock may be impacted by Ark's increased investment and the upcoming Q2 results. The company's development of a cancer vaccine with Merck could also influence the stock.
Ark's increased investment in Moderna indicates confidence in the company, which could influence other investors. However, the expected Q2 loss could negatively impact the stock. The development of a cancer vaccine with Merck could provide a potential growth driver for the company.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100